MXPA03003456A - Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv. - Google Patents

Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv.

Info

Publication number
MXPA03003456A
MXPA03003456A MXPA03003456A MXPA03003456A MXPA03003456A MX PA03003456 A MXPA03003456 A MX PA03003456A MX PA03003456 A MXPA03003456 A MX PA03003456A MX PA03003456 A MXPA03003456 A MX PA03003456A MX PA03003456 A MXPA03003456 A MX PA03003456A
Authority
MX
Mexico
Prior art keywords
ribavirin
combination therapy
interferon alfa
pegylated interferon
hcv combination
Prior art date
Application number
MXPA03003456A
Other languages
English (en)
Inventor
Junice Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA03003456A publication Critical patent/MXPA03003456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
MXPA03003456A 2000-10-18 2001-10-16 Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv. MXPA03003456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24155700P 2000-10-18 2000-10-18
PCT/US2001/032434 WO2002032414A2 (en) 2000-10-18 2001-10-16 Ribavirin-pegylated interferon alfa hcv combination therapy

Publications (1)

Publication Number Publication Date
MXPA03003456A true MXPA03003456A (es) 2003-07-14

Family

ID=22911172

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003456A MXPA03003456A (es) 2000-10-18 2001-10-16 Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv.

Country Status (13)

Country Link
US (1) US20020127203A1 (es)
EP (1) EP1326594A2 (es)
JP (1) JP2004511513A (es)
CN (1) CN1516599A (es)
AU (1) AU2002213343A1 (es)
BR (1) BR0114636A (es)
CA (1) CA2425522A1 (es)
HK (1) HK1052878A1 (es)
HU (1) HUP0301444A3 (es)
MX (1) MXPA03003456A (es)
NO (1) NO20031742L (es)
WO (1) WO2002032414A2 (es)
ZA (1) ZA200302525B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) 2000-05-26 2001-12-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
JP2005517648A (ja) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド 肝炎ウイルス感染症を治療するための組成物および方法
NZ533808A (en) * 2001-12-21 2005-03-24 Biopartners Gmbh Ribavirin granulate for producing coated tablets
KR20050035194A (ko) * 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
ES2469569T3 (es) 2002-06-28 2014-06-18 Idenix Pharmaceuticals, Inc. Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
WO2004058792A1 (en) * 2002-12-23 2004-07-15 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
LT2604620T (lt) 2003-05-30 2016-09-12 Gilead Pharmasset Llc Modifikuoti fluorintų nukleozidų analogai
WO2005016370A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd Method of treating viral infections
EP1706399A1 (en) * 2004-01-23 2006-10-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
BRPI0512360A (pt) * 2004-06-23 2008-03-11 Idenix Cayman Ltd derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae
JP4849622B2 (ja) 2004-08-11 2012-01-11 中外製薬株式会社 Ｈｃｖ感染症を治療または予防するための薬剤
CA2580457C (en) 2004-09-14 2014-11-04 Pharmasset, Inc. Preparation of 2'­fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
KR20090021163A (ko) * 2006-05-16 2009-02-27 도쿄 메트로폴리탄 오거니제이션 포 메디칼 리서치 Ｈｃｖ 감염증을 치료 또는 예방하기 위한 의약 조성물
US8277793B2 (en) * 2006-07-07 2012-10-02 Meiji Seika Pharma Co., Ltd. Prophylactic or therapeutic agent for viral disease
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8793074B2 (en) * 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8957199B2 (en) 2008-11-26 2015-02-17 Chugai Seiyaku Kabushiki Kaisha Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
PA8855701A1 (es) 2008-12-23 2010-07-27 Análogos de nucleósidos
JP5713919B2 (ja) 2008-12-23 2015-05-07 ギリアド ファーマセット エルエルシー ヌクレオシドホスホラミデート
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
EP2450051A4 (en) * 2009-06-30 2012-12-19 Meiji Seika Pharma Co Ltd MEDICAL AGENT AND METHOD FOR THE TREATMENT OF HARD-ANGLE CHRONIC HEPATITIS C
US20120177601A1 (en) * 2009-07-02 2012-07-12 The Usa As Represented By The Secretary Of The Department Of Veterans Affairs Treatment of hepatitis c virus infections
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
LT2709613T (lt) 2011-09-16 2018-02-12 Gilead Pharmasset Llc Žmogaus hepatito viruso (hcv) gydymo būdai
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DK2583677T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
TW201600087A (zh) 2011-10-21 2016-01-01 艾伯維有限公司 治療ｃ型肝炎病毒（ｈｃｖ）的方法
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
KR20150080592A (ko) 2012-11-02 2015-07-09 파마시클릭스, 인코포레이티드 Tec 패밀리 키나제 억제제 애쥬번트 요법
PE20151778A1 (es) 2013-01-31 2015-12-16 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CN1230198C (zh) * 1998-05-15 2005-12-07 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
JP2003507322A (ja) * 1998-12-18 2003-02-25 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
EP1140142A2 (en) * 1998-12-22 2001-10-10 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US6635646B1 (en) * 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy

Also Published As

Publication number Publication date
NO20031742D0 (no) 2003-04-15
EP1326594A2 (en) 2003-07-16
HK1052878A1 (zh) 2003-10-03
CA2425522A1 (en) 2002-04-25
US20020127203A1 (en) 2002-09-12
NO20031742L (no) 2003-06-17
WO2002032414A3 (en) 2003-04-03
BR0114636A (pt) 2004-02-10
JP2004511513A (ja) 2004-04-15
HUP0301444A3 (en) 2007-05-29
WO2002032414A2 (en) 2002-04-25
HUP0301444A2 (hu) 2003-11-28
AU2002213343A1 (en) 2002-04-29
ZA200302525B (en) 2004-07-21
CN1516599A (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
MXPA03003456A (es) Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv.
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
AU2157000A (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
ZA200301436B (en) Cripto tumour polypeptide.
MXPA02010787A (es) Peptidos modificados como agentes terapeuticos.
HK1050549A1 (en) Heater.
HK1041308A1 (zh) 烹飪用爐盤
MXPA01009262A (es) Conjunto de cubierta.
MXPA02001969A (es) Nuevas moleculas similares a interferon beta.
MXPA03008164A (es) Agentes anti-epileptogenos.
MXPA03007838A (es) Interferon alfa modificado con inmunogenicidad reducida.
EG23281A (en) Switch.
GB0003284D0 (en) Anti-viral therapy
AU148095S (en) Cooktop
ZA992276B (en) Oven.
AU150631S (en) Cooktop
GB0006787D0 (en) The ecotruck
DE60236449D1 (en) Neue alpha-oxidierte carbonsäure-phenethylamid-derivate
GB2368925B (en) Improved cooker
GB0012497D0 (en) Antiviral therapy
GB0103860D0 (en) Improved knob
GB2367242B (en) Antiviral treatment
ZA200000829B (en) Heating arrangement.
ZA200104920B (en) Cooking means.
GB0122973D0 (en) Lava fresh